Master of Science and Technology Commercialisation graduate, Lusia Guthrie, is CEO and Managing Director of LBT Innovations, an Australian biotech company that has recently been granted a US Patent for groundbreaking automated lab technology.

“LBT Innovations is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company was formed in 2004 and listed on the Australian Securities Exchange on 31 July 2006 (ASX: LBT). The focus of the Company has been the commercialisation of its first product, known as MicroStreak®, an automated agar plate streaking system which enables microbiology laboratories to process samples several times faster than can be done manually by a technician.

In 2007, LBT Innovations signed an agreement with French diagnostics giant bioMérieux to commercialise and market this invention, which is now known as PREVI™ Isola. This instrumentation product comprises a central part of bioMérieux’s FMLA™ (Full Microbiology Lab Automation™) strategy.

Going forward, LBT Innovations intends to continue its track record of innovation in microbiology, while also fully exploiting its existing commercial relationships.”